Ligand-independent androgen receptor activity

Scott M. Dehm, Donald J. Tindall

Research output: Chapter in Book/Report/Conference proceedingChapter


The androgen receptor (AR) is important for the growth and survival of normal and malignant prostate cells. As such, androgen-deprivation therapy is the current mainstay of systemic prostate cancer therapy. Invariably, prostate cancer will develop resistance to androgen deprivation and recur with a castration-recurrent phenotype. The surprising finding that castration-recurrent prostate cancer is still reliant on AR activity indicates that novel means of targeting the AR could be developed to treat this stage of the disease. Several mechanisms, including ligand-independent activation, have been described as means by which the AR can achieve a critical level of activity in castration-recurrent prostate cancer. This chapter will explore the mechanisms of ligand-independent AR activation and highlight some recent findings generated in the Tindall laboratory.

Original languageEnglish (US)
Title of host publicationAndrogen Action in Prostate Cancer
PublisherSpringer US
Number of pages23
ISBN (Print)9780387691770
StatePublished - 2009

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Ligand-independent androgen receptor activity'. Together they form a unique fingerprint.

Cite this